Literature DB >> 876312

Efficacy of preoperative and postoperative bone scanning in the management of breast carcinoma.

F H Gerber, J J Goodreau, P T Kirchner, W J Fouty.   

Abstract

With use of 99mtechnetium-labeled phosphates, we performed preoperative bone scans on 122 women with biopsy-proved breast carcinoma. Only two of the 110 patients with Stage I or II disease had scan abnormalities interpreted as bone metastases. Of 55 patients with normal preoperative scans, 20 later had changes suggesting bone metastases on the subsequent scans, most within 24 months of operation. In women with Stage I and II tumors, 13 of 48 (27 per cent) had scan evidence of bone metastasis of postoperative follow-up examination. Five of 23 with potential surgical cures (negative lymph nodes at operation) had bone metastasis within two years of operation. In Stage I and II patients, postoperative discovery of evolving metastases was most often (11 to 13) made by bone scan. Although the initial yield from preoperative bone scans is low, preoperative scanning combined with sequential postoperative scans constitutes one of the most sensitive indicators of evolving metastatic disease.

Entities:  

Mesh:

Year:  1977        PMID: 876312     DOI: 10.1056/NEJM197708112970603

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  10 in total

1.  The value of metastatic screening in early primary breast cancer.

Authors:  M C Barry; F Thornton; M Murphy; F Younis; R G Watson
Journal:  Ir J Med Sci       Date:  1999 Oct-Dec       Impact factor: 1.568

2.  Value of bone scanning in the follow-up of breast cancer patients. A study of 1000 cases.

Authors:  H Schünemann; P J Langecker; W Ellgas; A Leonhardt; H Merkl
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

3.  Bone scanning in breast cancer. Preliminary statement by British Breast Group on Bone Scanning.

Authors: 
Journal:  Br Med J       Date:  1978-07-15

4.  Baseline staging tests in primary breast cancer: a practice guideline.

Authors:  R E Myers; M Johnston; K Pritchard; M Levine; T Oliver
Journal:  CMAJ       Date:  2001-05-15       Impact factor: 8.262

5.  Routine bone scanning in patients with T1 and T2 breast cancer: a waste of money.

Authors:  K A Yeh; L Fortunato; J A Ridge; J P Hoffman; B L Eisenberg; E R Sigurdson
Journal:  Ann Surg Oncol       Date:  1995-07       Impact factor: 5.344

6.  Radionuclide evaluation of skeletal metastases: practical considerations.

Authors:  R H Gold; L W Bassett
Journal:  Skeletal Radiol       Date:  1986       Impact factor: 2.199

7.  An evaluation of clinical follow-up in women with early stage breast cancer among physician members of the American Society of Clinical Oncology.

Authors:  M S Simon; M Hoff; M Hussein; S Martino; A Walt
Journal:  Breast Cancer Res Treat       Date:  1993-09       Impact factor: 4.872

8.  CA15-3: a reliable indicator of metastatic bone disease in breast cancer patients.

Authors:  D P O'Brien; P G Horgan; D B Gough; R Skehill; H Grimes; H F Given
Journal:  Ann R Coll Surg Engl       Date:  1992-01       Impact factor: 1.891

Review 9.  Skeletal scintigraphy.

Authors:  I R McDougall
Journal:  West J Med       Date:  1979-06

10.  Characterising potential bone scan overuse amongst men treated with radical prostatectomy.

Authors:  Peter S Kirk; Tudor Borza; Megan E V Caram; Dean A Shumway; Danil V Makarov; Jennifer A Burns; Jeremy B Shelton; John T Leppert; Christina Chapman; Michael Chang; Brent K Hollenbeck; Ted A Skolarus
Journal:  BJU Int       Date:  2018-11-12       Impact factor: 5.588

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.